ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies. Our lead molecule, IM156, is a protein complex 1 (PC1) inhibitor that targets the Oxidative Phosphorylation (OXPHOS) pathway in mitochondria and decreases aberrant cell growth in fibrosis and select cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with a good tolerability. In fibrosis, ImmunoMet is currently conducting a Phase 1 study in healthy volunteers and plan to progress into Phase 2 PoC study in IPF patients in 4Q2021. The company was founded in 2015, is a spin-off from HanAll Biopharma, a Korean midsized public company, and has raised $31 MM post-spin-off.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Houston, Texas
- Phone
- 119196161923
- in****@****met.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- immunomet.com
- Keywords
- Fibrosis and Oncology.
- HQ
- Houston, Texas
Immunomet Therapeutics, Inc. Questions
Immunomet Therapeutics, Inc.'s helpline number is 119196161923
Immunomet Therapeutics, Inc.'s website is immunomet.com
Immunomet Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/immunomet-therapeutics-inc.
Immunomet Therapeutics, Inc. has
8 employees.
View email and phone details for 8
employees at Immunomet Therapeutics, Inc..
Immunomet Therapeutics, Inc.'s industry is
Biotechnology Research
Immunomet Therapeutics, Inc.'s top competitors are
Moleculin Biotech, Inc.,
Iterion Therapeutics,
Bellicum Pharmaceuticals, Inc.,
Radiomedix, Inc.,
Asylia Therapeutics,
Hope Biosciences,
Lantern Pharma Inc. (Nasdaq: Ltrn),
Colossal Biosciences,
Gradalis, Inc.,
Marker Therapeutics, Inc..
Immunomet Therapeutics, Inc.'s support email address is info@immunomet.com
Immunomet Therapeutics, Inc.'s categories are Biotechnology Research
Immunomet Therapeutics, Inc.'s founding year is 2015
